Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $15.72 Average Price Target from Analysts
Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ...
Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report released on ...
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today ...
Yahoo Finance9d
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...
Investors who Lost Money on Voyager Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - VYGR
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager ...
Did Voyager Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VYGR
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager ...
Insider Monkey22d
Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now
In this article, we are going to take a look at where Voyager Therapeutics, Inc. (NASDAQ:VYGR) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in ...
Morningstar2d
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will ...
Business Wire14d
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.